首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

1458102

全球干细胞治疗市场规模、份额、成长分析，按治疗（自体和同种异体）、按应用（再生医学、药物发现和开发）- 2024-2031 年行业预测

Global Stem Cell Therapy Market Size, Share, Growth Analysis, By Therapy(Autologous, and Allogenic), By Application(Regenerative Medicine, Drug Discovery and Development) - Industry Forecast 2024-2031

出版日期: 2024年03月25日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球干细胞治疗市场规模为121.1亿美元，预计将从2023年的133.3亿美元成长到2031年的287.9亿美元，预测期间（2024-2031年）复合年增长率为10.1%。

干细胞治疗产业的主要目标是为各种疾病提供尖端的解决方案。干细胞疗法的目标是治疗目前很少或没有有效替代疗法的疾病和损伤。该市场旨在利用干细胞的再生特性，为患有心血管疾病、神经系统疾病、骨科损伤、自体免疫疾病和某些癌症等疾病的患者带来希望。全球干细胞治疗市场的扩张。与年龄相关的疾病和慢性疾病的发生率上升是主要原因之一。

干细胞治疗的高价格是主要障碍之一。干细胞治疗市场面临许多障碍。监管和标准化的要求是主要障碍之一。随着这些治疗的进展，为干细胞疗法的开发、製造和临床应用建立精确的规范和标准变得越来越重要。成本效益和可扩展性是市场面临的两个问题。仍需要克服的一个主要障碍是增加干细胞疗法的产量以满足需求，同时保持品质和成本下降。儘管有困难，干细胞治疗市场仍呈现出巨大的潜力。越来越多的临床试验和研究调查干细胞疗法的潜力，预示着光明的未来。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

Novartis AG (Switzerland)
Pfizer Inc. (US)
Mesoblast Limited (Australia)
Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)
TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)
Gamida Cell Ltd. (Israel)
Vericel Corporation (US)
Medipost Co., Ltd. (South Korea)
Astellas Pharma Inc. (Japan)
Osiris Therapeutics, Inc. (US)
NuVasive, Inc. (US)
Cynata Therapeutics Limited (Australia)
Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)
Lonza Group Ltd. (Switzerland)
Caladrius Biosciences, Inc. (US)
Athersys, Inc. (US)
Cytori Therapeutics, Inc. (US)
Holostem Terapie Avanzate Srl (Italy)
Pluristem Therapeutics Inc. (Israel)
BioTime, Inc. (US)

简介目录

Product Code: SQMIG35H2162

Global Stem cell therapy Market size was valued at USD 12.11 Billion in 2022 and is poised to grow from USD 13.33 Billion in 2023 to USD 28.79 Billion by 2031, at a CAGR of 10.1% during the forecast period (2024-2031).

The main goal of the stem cell therapy industry is to offer cutting-edge solutions for a variety of illnesses. The goal of stem cell therapies is to treat illnesses and injuries for which there are currently few or no effective therapy alternatives. This market aims to give patients with ailments like cardiovascular diseases, neurological disorders, orthopedic injuries, autoimmune diseases, and some kinds of cancer hope by utilizing the regenerative characteristics of stem cells. the expansion of the market for stem cell therapy worldwide. The rising incidence of age-related illnesses and chronic disorders is one of the main causes.

The high price of stem cell treatments is one of the main obstacles. Numerous obstacles confront the market for stem cell therapy. The requirement for regulation and standardization is one of the main obstacles. Establishing precise norms and standards for stem cell therapy development, manufacturing, and clinical application is becoming more and more important as these treatments progress. Cost-effectiveness and scalability are two issues the market is facing. One major obstacle that still needs to be overcome is increasing the production of stem cell therapies to satisfy demand while keeping quality and costs down. Despite the difficulties, the market for stem cell therapy presents a lot of potential. A bright future is suggested by the growing number of clinical trials and research investigations examining the potential of stem cell therapy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Stem Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Stem Cell Therapy Market Segmental Analysis

The therapy, application, and geographic segments of the worldwide stem cell therapy market are divided up. The market is divided into two categories for therapy: autologous and allogeneic. The market is divided into three categories based on application: drug development, regenerative medicine, and discovery. The market is divided into Latin America, Middle East and Africa, Asia Pacific, North America, and Europe.

Drivers of the Global Stem Cell Therapy Market

One major factor propelling the stem cell therapy market is the increasing prevalence of chronic diseases like neurological illnesses, orthopedic injuries, and cardiovascular ailments. With the ability to repair damaged tissues and organs, stem cell therapies offer patients new therapy options when there are few or no other viable options.

Restraints in the Global Stem Cell Therapy Market

One major obstacle to the broad acceptance of stem cell therapies is their high cost. The cost of these treatments is considerable due in part to the complexity of manufacturing, research and development activities, and regulatory restrictions. This restricts many patients' access to stem cell treatments, especially in areas with lower incomes.

Market Trends of the Global Stem Cell Therapy Market

A greater emphasis is being placed on allogeneic therapies: these treatments, which employ donor cells, have become more popular. Benefits of this technique include lower production costs, uniform and easily accessible cell sources, and maybe off-the-shelf therapies. There is a growing pipeline of clinical trials and product development in the field of allogeneic cell therapy as a result of numerous companies refocusing their efforts on this area.

Personalized Medicine and Cell Banking: The field of personalized medicine, which involves customizing treatment plans for each patient according to their specific traits, is becoming more and more popular in the stem cell therapy industry. The process of collecting and preserving human cells for potential therapeutic applications, known as cell banking, is gaining significance. This strategy makes it possible to provide prompt, individualized treatment alternatives, especially in autologous therapies, which use the patient's own cells.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Stem Cell Therapy Market by Therapy

Market Overview
Autologous
and Allogenic

Global Stem Cell Therapy Market by Application

Market Overview
Regenerative Medicine
Drug Discovery and Development

Global Stem Cell Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (a subsidiary of Bristol Myers Squibb) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TiGenix NV (a subsidiary of Takeda Pharmaceutical Company Limited) (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gamida Cell Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medipost Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Osiris Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NuVasive, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cynata Therapeutics Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellular Dynamics International (a subsidiary of FUJIFILM Holdings Corporation) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Caladrius Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athersys, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytori Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Holostem Terapie Avanzate S.r.l. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pluristem Therapeutics Inc. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioTime, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments